Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “BIOVERATIV THERAPEUTICS INC.”

57 pharma patents match "BIOVERATIV THERAPEUTICS INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 57
Index total 30,257
Page 1 / 3

Quick answer

This filtered view shows 57 pharmaceutical patents matching "BIOVERATIV THERAPEUTICS INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

57 results for “BIOVERATIV THERAPEUTICS INC.” · 30,257 patents in full index Clear search

  1. US 12403183

    Factor VIII polypeptide formulations

    BIOVERATIV THERAPEUTICS INC. · Granted Sep 2, 2025 · Expires Aug 28, 2045

    granted
  2. US 12403164

    Lentiviral vector formulations

    BIOVERATIV THERAPEUTICS INC. · Granted Sep 2, 2025 · Expires Aug 28, 2045

    granted
  3. US 12371747

    Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy

    BIOVERATIV THERAPEUTICS INC. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  4. US 12364774

    Nucleic acid molecules and uses thereof for non-viral gene therapy

    BIOVERATIV THERAPEUTICS INC. · Granted Jul 22, 2025 · Expires Jul 17, 2045

    granted
  5. US 12257288

    Methods of inducing immune tolerance to clotting factors

    BIOVERATIV THERAPEUTICS INC. · Granted Mar 25, 2025 · Expires Mar 20, 2045

    granted
  6. US 12186375

    Factor VIII chimeric and hybrid polypeptides, and methods of use thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  7. US 12173307

    Methods for the purification of viral vectors

    BIOVERATIV THERAPEUTICS INC. · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  8. US 12161696

    Methods of treating hemophilic arthropathy using chimeric clotting factors

    BIOVERATIV THERAPEUTICS INC. · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  9. US 12128092

    Lyophilized factor IX formulations

    BIOVERATIV THERAPEUTICS INC. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  10. US 12030925

    Methods of treating hemophilia A

    BIOVERATIV THERAPEUTICS INC. · Granted Jul 9, 2024 · Expires Jul 4, 2044

    granted
  11. US 11753461

    Optimized factor VIII genes

    BIOVERATIV THERAPEUTICS INC. · Granted Sep 12, 2023 · Expires Sep 7, 2043

    granted
  12. US 11685771

    Recombinant factor VIII proteins

    BIOVERATIV THERAPEUTICS INC. · Granted Jun 27, 2023 · Expires Jun 22, 2043

    granted
  13. US 11642398

    Factor IX polypeptide formulations

    BIOVERATIV THERAPEUTICS INC. · Granted May 9, 2023 · Expires May 4, 2043

    granted
  14. US 11401322

    Immunoglobulin chimeric monomer-dimer hybrids

    BIOVERATIV THERAPEUTICS INC. · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted
  15. US 11370827

    Chimeric factor VIII polypeptides and uses thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Jun 28, 2022 · Expires Jun 23, 2042

    granted
  16. US 11372008

    Blood factor monitoring assay and uses thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Jun 28, 2022 · Expires Jun 23, 2042

    granted
  17. US 11286528

    Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy

    BIOVERATIV THERAPEUTICS INC. · Granted Mar 29, 2022 · Expires Mar 24, 2042

    granted
  18. US 11266720

    Factor VIII-FC chimeric and hybrid polypeptides, and methods of use thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Mar 8, 2022 · Expires Mar 3, 2042

    granted
  19. US 11261437

    Procoagulant compounds

    BIOVERATIV THERAPEUTICS INC. · Granted Mar 1, 2022 · Expires Feb 24, 2042

    granted
  20. US 11225650

    Methods of using FIX polypeptides

    BIOVERATIV THERAPEUTICS INC. · Granted Jan 18, 2022 · Expires Jan 13, 2042

    granted
  21. US 11192936

    Factor VIII chimeric proteins and uses thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Dec 7, 2021 · Expires Dec 2, 2041

    granted
  22. US 11168125

    Immunoglobulin chimeric monomer-dimer hybrids

    BIOVERATIV THERAPEUTICS INC. · Granted Nov 9, 2021 · Expires Nov 4, 2041

    granted
  23. US 11168316

    Chimeric clotting factors

    BIOVERATIV THERAPEUTICS INC. · Granted Nov 9, 2021 · Expires Nov 4, 2041

    granted
  24. US 11091534

    Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Aug 17, 2021 · Expires Aug 12, 2041

    granted